Urgent Bite 167 -Thinking about Health Literacy
The health literacy of our patients is an important consideration in urgent care.
Urgent Bite 166 – Torticollis
What are the red flags when we see a patient with torticollis?
Urgent Bite 165 – Thinking about SUFE
SUFEs will often first present in primary care and are easily missed.
Urgent Bite 164 – Thinking about Leukonychia and CPD
Not everything that comes through UC is urgent, but knowing a little about these out-of-scope topics is still necessary.
COVID-19 Disability Data review
a news article from Whaikaha about data from the Ministry of Health – Manatū Hauora on COVID-19 on case rates, hospitalisations and mortality rates for people who receive Disability Support Services. There are links to the report
Remuneration/workforce survey 2023
Thank you those who responded. This year a record 150 doctors replied to the workforce survey. Nine were General Practitioners, 73 were Fellows of the College and this year we divided registrars into senior (34 replies) and junior (16 replies). This represents about 3/8 of RNZCUC members but may not be directly comparable to last…
Urgent Bite 163 – Hypopyon
Looking for and identifying a hypopyon is an important part of the UC eye exam.
Urgent Bite 162 – Seidel’s Test
We should all know how to do Seidel’s test in urgent care.
Guideline for Management of Severe Asymptomatic Hypertension in Urgent Care
Author: Dr Gustav Fourie
2019
Abstract:
Hypertension is a common presentation but there is no New Zealand based guideline for the management of severe asymptomatic hypertension (greater than 180 systolic or 110 diastolic) in urgent care. Definitions have varied in both naming ( hypertensive emergency, hypertensive urgency, hypertensive crisis ,malignant hypertension,accelerated hypertension, severe asymptomatic hypertension) and parameters.
Method:
A review of recent literature was conducted.
Rivaroxaban as bridging agent for suspected DVT
Author: Dr Gary Mitchell
Abstract:
Rivaroxaban is well established as a treatment for deep vein thrombosis and pulmonary embolism, but there has been hesitation in using it as a bridging agent in clinical situations where DVT is suspected but not yet confirmed by definitive ultrasound scan. The evidence for the safety and efficacy of this approach is explored. During this time of research, the use of rivaroxaban began to gain acceptance and usage in New Zealand, leading to a brief analysis of factors involved in trying to introduce up to date guidelines into a small health organisation in New Zealand prior to widespread acceptance and definitive guidelines at District Health Board level.